Comparative Dose- and Time-Dependent Manner of Resveratrol on Human Epithelial Cell Types

• Published in: Revista Brasileira de Farmacognosia
• Main Author: Effendy W.N.F.W.E.; S. M. N. Mydin R.B.; Shanker K.; Ng K.Y.; Sundaraju P.; Gunasagaran S.; Ahmad Sopian S.F.; Mohd Gazzali A.
• Format: Article
• Language: English
• Published: Springer Science and Business Media Deutschland GmbH 2022
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129841158&doi=10.1007%2fs43450-022-00257-7&partnerID=40&md5=150aa5f3e0c9bababc455b15c0a99fca

Resveratrol is a conventional nutraceutical compound that has been extensively studied for therapeutic applications, especially cancer therapy; however, its positive therapeutical proprieties are balanced by its negative effects. Presently, the therapeutic functionalities of resveratrol for nasopharyngeal carcinoma, osteosarcoma, and human embryonic cell lines, in terms of optimum dose and time profile, were determined. Epithelial cancer cells originating from the nasopharynx (C666-1, NPC/HK-1), bone (SaOS-2), and kidney (HEK 293) were extensively studied in the current work. NPC cells were exposed to various concentrations of resveratrol (0.16–20.00 μM), individually. Meanwhile, SaOS-2 and HEK 293 were treated with resveratrol of 3.125–200 μM in concentration. The half-maximal inhibitory effect of resveratrol was spectrophotometrically measured at 490 nm. The dose-dependent evaluation showed the inhibitory effect of resveratrol on NPC cell lines while increasing cell proliferation on SaOS-2 and HEK-293 cell lines. After 48 h of incubation, the IC50 value of the NPC cell lines was approximately 3.75 μM for C666-1 and NPC/HK-1. By contrast, the multiplication growth of SaOS-2 and HEK 293 was more than 300% at increased resveratrol concentration. These results depict the enhanced double effect of resveratrol and its potential use in cancer therapy which effectiveness should be further investigated. Graphical abstract: [Figure not available: see fulltext.]. © 2022, The Author(s) under exclusive licence to Sociedade Brasileira de Farmacognosia.